ReviewFrontiers in chemistry2025
The quinoline framework and related scaffolds in natural products with anti-
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Discovery of Potential Antileishmanial Compounds Through Phenotypic Screening of an Alkaloid Library.Molecules (Basel, Switzerland) · 2025Article
- Current developments of metal- and metalloid-based quinoline compounds as leishmanicidal agents.Frontiers in chemistry · 2025Review
- A comprehensive revision on the use of quinoline antimalarial drugs as leishmanicidal agents.Frontiers in chemistry · 2025Review
- Application of nano and microformulations to improve the leishmanicidal response of quinoline compounds: a brief review.Frontiers in chemistry · 2025Review
- Quinolines: the role of substitution site in antileishmanial activity.Frontiers in chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For almost one hundred years, the quinoline heterocycle has been recognized as a privileged pharmacophore in anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.